Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312. SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally. The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations. The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy. |
Auto industry insiders highlight interdependence between China, EuropeAlabama lawmakers advance bill that could lead to prosecution of librariansPictured: PlantAP Week in Pictures: GlobalPackers take Arizona offensive tackle Jordan Morgan with 25th overall pick in NFL draftGrace Kim shoots 7China to launch ShenzhouHere are 14 football players to watch next season from current Big 12 Conference schoolsGrace Kim shoots 7The 49ers take Florida receiver Ricky Pearsall with the 30th pick in the NFL draft